获得Nucleis,加强欧洲的PET药物制造和病人护理。 Curium acquires Nucleis, enhancing PET drug manufacturing and patient care in Europe.

Curium是一家领先的核医学公司,它收购了PET放射性制药专家Nucleis。 Curium, a leading nuclear medicine company, has acquired Nucleis, a PET radiopharmaceutical specialist. 这一举措增加了Curium在PET制药生产能力,并加强了其在欧洲的存在,特别是在贝内卢克斯地区. This move boosts Curium's capacity in PET drug manufacturing and strengthens its European presence, particularly in the Benelux region. 购置设备将改善获得肿瘤学、神经学和心脏病学关键诊断的机会,加强病人护理,支持开发新的PET追踪器。 The acquisition will improve access to critical diagnostics in oncology, neurology, and cardiology, enhancing patient care and supporting the development of new PET tracers.